Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer

Korábbi kezelés

• Untreated CNS metastases or symptomatic CNS metastases requiring escalating doses of corticosteroids
  • PATIENT CHARACTERISTICS:
• Ability to understand and the willingness to sign a written informed consent document
  • PRIOR CONCURRENT THERAPY:
• No ≥ grade 2 toxicity from prior therapy (other than alopecia)
• No other concurrent investigational agents
• No other concurrent anticancer therapy

Más betegség

• No known history of allergic reactions to paclitaxel
• No serious or uncontrolled infection
• See Disease Characteristics
• No taxane for adjuvant therapy or metastatic disease within the past 12 months

Laborértékek

• WBC ≥ 3,000/mm³
• ANC ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Hemoglobin ≥ 9.0 g/dL
• AST and ALT ≤ 2.5 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 2.5 times ULN (unless bone metastases are present in the absence of liver metastases)
• Bilirubin ≤ 1.5 mg/dL
• Creatinine clearance ≥ 30 mL/min (calculated or 24-hour)

Egyéb

• Karnofsky performance status 70-100%
• Peripheral neuropathy ≤ grade 1
• Negative pregnancy test
• Fertile patients must use effective contraception
• Not pregnant or nursing

• Diagnosis of metastatic breast cancer
• Any estrogen receptor, progesterone receptor, or HER-2/neu status allowed as long as the patient will receive paclitaxel albumin-stabilized nanoparticle formulation alone
• First- or second-line chemotherapy treatment for metastatic disease planned

A regiszterben nem jelölt feltételek

• DISEASE CHARACTERISTICS: